Neogen updates timeline on Zoetis genomics sale amid antitrust review
Neogen said regulatory clearance for its genomics business sale to Zoetis is now expected to conclude in early 2027 after Zoetis offered to divest assets in Australia.
Neogen Corporation disclosed in an 8-K filed for a November 4, 2026 report date that on March 2, 2026, it had entered into a definitive agreement to sell its global Genomics business to Zoetis Inc.1 The filing noted that the transaction remains subject to customary closing conditions and regulatory approvals.1
According to the filing, both companies continue to cooperate with the Australian Competition and Consumer Commission and the New Zealand Commerce Commission in their ongoing reviews of the transaction.1
Neogen said that to assist the regulatory clearance process, Zoetis has recently offered to divest certain assets in Australia, and as a result the companies expect regulatory review to conclude in early 2027.1
The 8-K was signed by R. Bryan Riggsbee, Chief Financial Officer of Neogen, dated November 4, 2026. No further financial terms of the transaction, including sale price or structure, were disclosed in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.